Imunon, Inc. Announces Director Departure and Election
Ticker: IMNN · Form: 8-K · Filed: May 20, 2024 · CIK: 749647
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Imunon's board sees a change: Dr. Costales out, Dr. Roth in. Exec pay also adjusted.
AI Summary
On May 15, 2024, Imunon, Inc. filed an 8-K report detailing the departure of Director Dr. Nicholas B. Costales and the election of Dr. Jonathan S. Roth as a new director. The company also announced changes to its executive compensation arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's direction and stability.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Dr. Nicholas B. Costales (person) — Departing Director
- Dr. Jonathan S. Roth (person) — Newly Elected Director
- May 15, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from Imunon, Inc.'s board of directors?
Dr. Nicholas B. Costales has departed from Imunon, Inc.'s board of directors as of May 15, 2024.
Who has been elected as a new director to Imunon, Inc.'s board?
Dr. Jonathan S. Roth has been elected as a new director to Imunon, Inc.'s board.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 15, 2024.
What other items are covered in this 8-K filing besides director changes?
This 8-K filing also covers the election of directors and compensatory arrangements of certain officers.
What is Imunon, Inc.'s state of incorporation?
Imunon, Inc. is incorporated in Delaware.
Filing Stats: 1,111 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2024-05-20 08:30:21
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
- $10,000 — urch will be paid a monthly retainer of $10,000, plus an additional $250 for each hour
- $250 — retainer of $10,000, plus an additional $250 for each hour of services performed in
- $428,615.00 — ii) a retirement bonus in the amount of $428,615.00. Mr. Church will also remain eligible t
- $35,000 — Agreement, the Company will pay Monomoy $35,000 per month for Mr. Gaiero's service as t
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 92KB
- ex10-2.htm (EX-10.2) — 80KB
- 0001493152-24-020543.txt ( ) — 422KB
- imnn-20240515.xsd (EX-101.SCH) — 3KB
- imnn-20240515_lab.xml (EX-101.LAB) — 33KB
- imnn-20240515_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Dated: May 20, 2024 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President, Chief Financial Officer and Corporate Secretary